Bristol Myers Squibb is once again piling on the cash for Immatics, a German immunotherapy biotech. The Big Pharma has tripled down on the collaboration, which originally kicked off in 2019 and was added to in 2021. BMS is paying $60 million upfront and $700 million in biobucks down the line for at least two new programs. And there's more: Bristol expanded the 2019 collaboration, with another $20 million plus milestones and royalties. Also under discussion is Fierce Pharma’s special report on the world’s 20 top-selling drugs. COVID-19 vaccines by Pfizer and Moderna are listed among the top three. And COVID treatments from Regeneron/Roche and Gilead were also in the top 20.

Lastly, we have bloopers. After just over a month of creating this podcast, we finally have some “behind-the-scenes" tape to share.

To learn more about the topics in this episode: 
The top 20 drugs by worldwide sales in 2021
ASCO preview: How Gilead, Pfizer, AstraZeneca-Daiichi breast cancer data may—or may not—change treatment practice
ASCO: Mirati cedes to Amgen's Lumakras on durability in tight KRAS battle
SKYLARK sings: Sage, Biogen hatch positive phase 3 data in postpartum depression
GSK strikes $3.3B Affinivax buyout to MAP out challenge to Pfizer's blockbuster pneumococcal vaccine
Pfizer, already flush with cash, will reap $16B from selling shares in GSK consumer health spinoff
Roche's Evrysdi ramps up SMA rivalry with Novartis and Biogen thanks to FDA nod in newborns
Novartis' Kymriah bags FDA nod to face off against Gilead's Yescarta in follicular lymphoma
UPDATE: Bristol Myers triples-down on Immatics, bringing deal to $4.2B total biobucks. Why not just buy it?

The Top Line is produced by senior multimedia producer Teresa Carey with editor-in-chief Tracy Staton, managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists.

Bristol Myers Squibb is once again piling on the cash for Immatics, a German immunotherapy biotech. The Big Pharma has tripled down on the collaboration, which originally kicked off in 2019 and was added to in 2021. BMS is paying $60 million upfront and $700 million in biobucks down the line for at least two new programs. And there's more: Bristol&nbsp;expanded the 2019 collaboration, with another $20 million plus milestones and royalties. Also under discussion is Fierce Pharma&rsquo;s special report on the world&rsquo;s 20 top-selling drugs. COVID-19 vaccines by Pfizer and Moderna are listed among the top three. And&nbsp;COVID treatments from Regeneron/Roche and Gilead were also in the top 20.
Lastly, we have bloopers. After just over a month of creating this podcast, we finally have some &ldquo;behind-the-scenes" tape to share.
To learn more about the topics in this episode:&nbsp;
<ul>
<li><a href="https://www.fiercepharma.com/special-reports/top-20-drugs-worldwide-sales-2021" data-cke-saved-href="https://www.fiercepharma.com/special-reports/top-20-drugs-worldwide-sales-2021">The top 20 drugs by worldwide sales in 2021</a></li>
<li><a href="https://www.fiercepharma.com/pharma/asco-preview-how-gilead-pfizer-astrazeneca-daiichi-breast-cancer-data-may-or-not-change" data-cke-saved-href="https://www.fiercepharma.com/pharma/asco-preview-how-gilead-pfizer-astrazeneca-daiichi-breast-cancer-data-may-or-not-change">ASCO preview: How Gilead, Pfizer, AstraZeneca-Daiichi breast cancer data may&mdash;or may not&mdash;change treatment practice</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/asco-mirati-cedes-amgens-lumakras-durability-tight-kras-battle" data-cke-saved-href="https://www.fiercebiotech.com/biotech/asco-mirati-cedes-amgens-lumakras-durability-tight-kras-battle">ASCO: Mirati cedes to Amgen's Lumakras on durability in tight KRAS battle</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/skylark-sings-sage-biogen-hatch-positive-phase-3-data-postpartum-depression" data-cke-saved-href="https://www.fiercebiotech.com/biotech/skylark-sings-sage-biogen-hatch-positive-phase-3-data-postpartum-depression">SKYLARK sings: Sage, Biogen hatch positive phase 3 data in postpartum depression</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/gsk-strikes-21b-affinivax-buyout-map-out-challenge-blockbuster-pfizer-vaccine" data-cke-saved-href="https://www.fiercebiotech.com/biotech/gsk-strikes-21b-affinivax-buyout-map-out-challenge-blockbuster-pfizer-vaccine">GSK strikes $3.3B Affinivax buyout to MAP out challenge to Pfizer's blockbuster pneumococcal vaccine</a></li>
<li><a href="https://www.fiercepharma.com/pharma/pfizer-plans-16b-exit-gsk-consumer-health-joint-venture-after-spinoff" data-cke-saved-href="https://www.fiercepharma.com/pharma/pfizer-plans-16b-exit-gsk-consumer-health-joint-venture-after-spinoff">Pfizer, already flush with cash, will reap $16B from selling shares in GSK consumer health spinoff</a></li>
<li><a href="https://www.fiercepharma.com/pharma/genentechs-evrysdi-gains-key-label-expansion-allowing-its-use-babies-spinal-muscular-atrophy" data-cke-saved-href="https://www.fiercepharma.com/pharma/genentechs-evrysdi-gains-key-label-expansion-allowing-its-use-babies-spinal-muscular-atrophy">Roche's Evrysdi ramps up SMA rivalry with Novartis and Biogen thanks to FDA nod in newborns</a></li>
<li><a href="https://www.fiercepharma.com/marketing/novartis-kymriah-bags-fda-nod-face-gileads-yescarta-follicular-lymphoma" data-cke-saved-href="https://www.fiercepharma.com/marketing/novartis-kymriah-bags-fda-nod-face-gileads-yescarta-follicular-lymphoma">Novartis' Kymriah bags FDA nod to face off against Gilead's Yescarta in follicular lymphoma</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/bristol-myers-triples-down-immatics-bringing-deal-42b-total-biobucks-why-not-just-buy-it" data-cke-saved-href="https://www.fiercebiotech.com/biotech/bristol-myers-triples-down-immatics-bringing-deal-42b-total-biobucks-why-not-just-buy-it">UPDATE: Bristol Myers triples-down on Immatics, bringing deal to $4.2B total biobucks. Why not just buy it?</a></li>
</ul>
The Top Line is produced by senior multimedia producer Teresa Carey with editor-in-chief Tracy Staton, managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our &ldquo;Fierce&rdquo; journalists.

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Advertisement